EUVIMEDEUVIMED entdecken
CrossrefInfokarte

EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP

W J Fokkens, E De Corso, V Backer, M Bernal-Sprekelsen, L Bjermer, C von Buchwald, A Chaker, Z Diamant, P Gevaert, J Han, C Hopkins, V Hox, L Klimek, V J Lund, S Lee, A Luong, J Mullol, A Peters, O Pfaar, S Reitsma, S Toppila-Salmi, G K Scadding, A R Sedaghat, A-S Viskens, M Wagenmann, P W Hellings

Rhinology Journal · 2024-01-01 · 0-0

DOI: 10.4193/rhin23.415 ↗
AbstractBibliografische Angaben

Abstract

Severe chronic rhinosinusitis with nasal polyps (CRSwNP), a form of diffuse bilateral (usually type 2) CRS, is a debilitating disease with a significant impact on quality of life (QoL). With novel knowledge and treatment options becoming available, there is a growing need to update or revise key definitions to enable communication across different specialties dealing with CRS, and to agree on novel goals of care in CRSwNP. The European Forum for Research and Education in Allergy and Airway diseases (EUFOREA) and EPOS expert members discussed how to measure treatment responses and set new treatment goals for CRSwNP. In this paper a consensus on a list of definitions related to CRSwNP is provided: control, remission, cure, recurrence/exacerbation, treatable traits, remodeling, progression, and disease modification. By providing these definitions, the involved experts hope to improve communication between all stakeholders involved in CRSwNP treatment for use in routine care, basic and clinical research and international guidelines aimed to harmonize and optimize standard of care of patients with CRSwNP in the future.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →